Developer docs
API playgroundTry for free, no card

Search company profiles

Ondine Biomedical

Full company profile

uuid0000gte

Namestring
Ondine Biomedical
Legal namestring
Ondine Biomedical Inc.
Websiteurl
ondinebio.com
Company typeenum
Public
Founded yearint
1999
Descriptiontext

Ondine Biomedical Inc. is a Canadian clinical-stage life sciences company headquartered in Vancouver, British Columbia, and listed on the AIM market of the London Stock Exchange (ticker: OBI) since December 2021. The company has built a patented photodisinfection platform — an antimicrobial photodynamic therapy (aPDT) that applies a photosensitizing solution to a treatment site and activates it with non-thermal laser light, generating singlet oxygen that destroys pathogens through oxidative burst; the reaction ceases immediately when the light source is removed. The lead commercial product, Steriwave™, is a rapid nasal decolonization system that eradicates Staphylococcus aureus, MRSA, Candida auris, SARS-CoV-2 and related pathogens in a single five-minute, nurse-administered pre-surgical treatment, eliminating the patient-compliance burden of multi-day topical antibiotic protocols.

Steriwave is CE-marked in Europe, holds FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for the United States, and is classified as an Innovation Product by NHS Supply Chain in the United Kingdom. Real-world clinical outcomes range from a 66% to 84% reduction in surgical site infections across cohorts including Vancouver General Hospital (10-year longitudinal data), Leeds Teaching Hospitals (78.5% reduction in complex brain surgery), and Mid Yorkshire Teaching NHS Trust (71% reduction). The company is currently running the pivotal Phase 3 LANTERN trial under FDA review, with 93%+ enrollment across 14 HCA Healthcare sites and four Canadian centers (5,200+ patients) and top-line results expected in Spring 2026.

Ondine generates revenue from sales of Steriwave capital equipment and recurring per-procedure consumables into hospitals, with FY2025 revenue of CAD 2.6 million (~29% YoY growth) and a customer footprint of 37 hospitals across Canada, the United Kingdom, and international pilot markets (Spain, Germany, Mexico). Distribution is primarily direct in Canada and through Mölnlycke Health Care in the United Kingdom, with HCA Healthcare acting as both a clinical-development partner for the US Phase 3 program and as a UK commercial channel. Beyond Steriwave, Ondine has four pipeline indications — chronic rhinosinusitis, burn and wound decolonization, endotracheal tube disinfection to prevent ventilator-associated pneumonia, and topical antiviral therapy for upper respiratory viruses — which extend the platform TAM but contribute no current revenue. The company has reported a CAD 29.5 million net loss in FY2025, driven principally by over CAD 21 million in LANTERN trial R&D spend.

Short descriptiontext

Ondine Biomedical (LSE: OBI) is a Vancouver-based clinical-stage life sciences company that has commercialized Steriwave™, a CE-marked, FDA Fast Track-designated photodisinfection nasal decolonization therapy that reduces surgical site infections without contributing to antimicrobial resistance, sold to hospitals across Canada, the UK, and selected international markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial photodynamic therapy, nasal decolonization therapy, infection prevention devices, non-antibiotic antimicrobial treatment, surgical site infection prevention
Industry1 code
PRIMARYHLAHANAD
Disinfection & Surface Decontamination (Wipes, Sprays, Fogging, UV Robots)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Antimicrobial medical devices
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Steriwave Device and Consumables Sales
TypeHardware Sales
Description

Sale of Steriwave photodisinfection system (capital equipment) and associated consumable components for nasal photodisinfection treatments. Revenue generated from hospital deployments and per-procedure consumables. FY2025 revenue was CAD 2.6 million with 29% year-over-year growth, driven by expanding hospital customer base.

investing.com
2Product Pipeline Development
TypeLicensing Royalties
Description

Development-stage products include chronic rhinosinusitis treatment, burn/wound decolonization, endotracheal tube disinfection for ventilator-associated pneumonia prevention, and topical antiviral therapy for upper respiratory tract including SARS-CoV-2. These pipeline products represent future revenue potential as they receive regulatory approvals.

investing.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Steriwave™
Description

Rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics.

ondinebio.com
Core offering1 text field

Ondine Biomedical develops and commercializes Steriwave, a light-activated antimicrobial photodisinfection medical device that performs rapid 5-minute nasal decolonization to eliminate pathogens (bacteria, viruses, fungi including MRSA, Staphylococcus aureus, Candida auris, and SARS-CoV-2) associated with healthcare-associated infections. The proprietary platform combines a photosensitizing solution with non-thermal laser light at specific wavelengths to generate singlet oxygen that destroys pathogens through oxidative burst without contributing to antimicrobial resistance. The product is sold as capital equipment together with per-procedure consumables to hospitals and healthcare systems for pre-surgical and ICU infection prevention.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Up to 84% reduction in surgical site infections at Vancouver General Hospital over past decade
+5 more records
Product overview1 text field

Ondine Biomedical Inc. is a Canadian life sciences company that has developed a patented photodisinfection platform technology for preventing and treating infections. The company's lead commercial product is Steriwave™, a rapid nasal decolonization therapy that eradicates pathogens in minutes using light-activated antimicrobial technology. The technology has been deployed in Canadian and UK hospitals, demonstrating up to 84% reduction in surgical site infections. The company also maintains a pipeline of products in development including treatments for chronic rhinosinusitis, burn and wound decolonization, endotracheal tube disinfection for ventilator-associated pneumonia prevention, and topical antiviral therapy for upper respiratory tract infections.

Product and service1 record
1Steriwave Nasal Photodisinfection System
CategoryAntimicrobial medical devices
Description

Steriwave is a light-activated antimicrobial medical device that performs rapid 5-minute nasal decolonization to eradicate a broad spectrum of pathogens (Staphylococcus aureus, MRSA, Candida auris, SARS-CoV-2 and other superbugs) in the nose. Designed for nurse-led in-clinic administration in hospitals, it eliminates pathogens associated with healthcare-associated infections without contributing to antimicrobial resistance. Real-world deployments at Vancouver General Hospital demonstrated up to 84% reduction in surgical site infections over the past decade.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

Research collaboration with Europe's highly ranked medical institution to pilot Steriwave in ENT patients, marking first German hospital pilot.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-02
Description

Royal Papworth Hospital, one of the world's foremost cardiothoracic centres, launching pilot program with Steriwave for complex cardiac surgeries.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-05-12
Description

Membership in CAN Health Network provides strategic support, insights and connections as Ondine works to scale its infection prevention technology across Canada.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-19
Description

Partnership for ICU pilot study (SMURF) evaluating nasal photodisinfection in critically ill patients. Study results accepted for publication in Journal of Critical Care, marking first-ever deployment of this therapy in ICU setting. Foundation provided research support and funding.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-06
Description

Dr. Paul Nix-led study at Leeds demonstrated 78.5% reduction in SSIs in complex brain surgery. Study results accepted for publication in Journal of Laryngology & Otology. Funded in part by Leeds Hospitals Charity.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-04-10
Description

HCA Healthcare UK, one of the UK's leading private healthcare providers operating 30+ facilities, authorized Steriwave for use across its healthcare facilities. Professor Claire Hopkins at London Bridge Hospital demonstrated a 77% reduction in antibiotic use in endoscopic sinus surgery patients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-27
Description

HCA Healthcare is a key strategic partner conducting the pivotal Phase 3 LANTERN clinical trial across 14 US hospitals with over 5,200 patients. HCA invested US$4 million in Ondine and is partnered for FDA regulatory submission. HCA Healthcare is the largest healthcare system in the US with 184 hospitals and 2,000+ sites of care.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-09-23
Description

Mölnlycke Health Care serves as the UK distribution partner for Steriwave following partnership announced September 2023. Mölnlycke distributes the technology to NHS providers through NHS Supply Chain, enabling broad UK market access.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

Partnership deploying Steriwave at two hospitals resulted in 71% reduction in post-surgical infections. Partnership won Excellence in Healthcare Partnership Award and shortlisted for HSJ Partnership Award. Technology now being evaluated across hospitals in England.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

PDI's Prevantics and other nasal antiseptic products directly compete with Steriwave in the pre-surgical nasal decolonization category, targeting the same hospital infection-prevention buyers and similar clinical indications. Both compete for SSI reduction protocols in US hospitals.

2Steris
TypeBroad incumbent
Description

Steris is a large, publicly-listed sterilization and infection-prevention company serving hospitals and life sciences with capital equipment, consumables, and services. It is an incumbent comparator for any hospital-grade antimicrobial/sterilization technology play, including Steriwave's infection-prevention value proposition.

TypeBroad incumbent
Description

3M's Health Care division sells skin and nasal antiseptics, surgical drapes, and infection-prevention products into the same hospital procurement channels as Steriwave. It is a broad incumbent competing for hospital infection-prevention budgets and SSI-reduction protocols.

TypeOthers
Description

Mölnlycke is Ondine's UK distribution partner for Steriwave through NHS Supply Chain, and is itself a leading global wound care and infection-prevention company. Comparable as an infection-prevention participant serving hospitals, with direct overlap on the UK commercial channel.

TypeEmerging player
Description

Noxilizer provides nitrogen dioxide-based no-touch sterilization for medical devices and pharmaceutical manufacturing. Comparable as an emerging non-traditional antimicrobial technology company targeting healthcare infection-prevention use cases adjacent to Steriwave.

TypeEmerging player
Description

Bioquell (now part of Ecolab) provides hydrogen peroxide vapor bio-decontamination systems for hospital rooms and life sciences facilities. Comparable as an emerging technology vendor in hospital infection prevention with overlap on HAI reduction value propositions.

TypeEmerging player
Description

DenMat has historically offered Periowave and other light-activated antimicrobial products in dentistry, using a related photodisinfection approach. It is the closest direct comparable in photodynamic antimicrobial therapy, though operating in dental rather than hospital infection prevention.

TypeEmerging player
Description

Theralase is a clinical-stage photodynamic therapy company developing light-activated therapeutics for cancer and infections. Comparable as a small-cap photodynamic therapy peer with similar scientific underpinnings to Ondine's photodisinfection platform.

TypeBroad incumbent
Description

Clorox Healthcare is a major incumbent in healthcare environmental disinfection (wipes, bleach cleaners, UV systems) sold into the same hospital infection-prevention channels as Steriwave. Comparable as a broad disinfectant incumbent competing for hospital HAI-reduction budgets.

TypeRegional player
Description

Xttrium manufactures antiseptic and skin-prep products including chlorhexidine applicators used in US hospital decolonization protocols. Comparable as a US-focused antiseptic manufacturer competing with Steriwave for the pre-surgical nasal decolonization indication.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ondine Biomedical

Antimicrobial medical devicesondinebio.com

Ondine Biomedical (LSE: OBI) is a Vancouver-based clinical-stage life sciences company that has commercialized Steriwave™, a CE-marked, FDA Fast Track-designated photodisinfection nasal decolonization therapy that reduces surgical site infections without contributing to antimicrobial resistance, sold to hospitals across Canada, the UK, and selected international markets.

What Ondine Biomedical does

Ondine Biomedical Inc. is a Canadian clinical-stage life sciences company headquartered in Vancouver, British Columbia, and listed on the AIM market of the London Stock Exchange (ticker: OBI) since December 2021. The company has built a patented photodisinfection platform — an antimicrobial photodynamic therapy (aPDT) that applies a photosensitizing solution to a treatment site and activates it with non-thermal laser light, generating singlet oxygen that destroys pathogens through oxidative burst; the reaction ceases immediately when the light source is removed. The lead commercial product, Steriwave™, is a rapid nasal decolonization system that eradicates Staphylococcus aureus, MRSA, Candida auris, SARS-CoV-2 and related pathogens in a single five-minute, nurse-administered pre-surgical treatment, eliminating the patient-compliance burden of multi-day topical antibiotic protocols.

Steriwave is CE-marked in Europe, holds FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for the United States, and is classified as an Innovation Product by NHS Supply Chain in the United Kingdom. Real-world clinical outcomes range from a 66% to 84% reduction in surgical site infections across cohorts including Vancouver General Hospital (10-year longitudinal data), Leeds Teaching Hospitals (78.5% reduction in complex brain surgery), and Mid Yorkshire Teaching NHS Trust (71% reduction). The company is currently running the pivotal Phase 3 LANTERN trial under FDA review, with 93%+ enrollment across 14 HCA Healthcare sites and four Canadian centers (5,200+ patients) and top-line results expected in Spring 2026.

Ondine generates revenue from sales of Steriwave capital equipment and recurring per-procedure consumables into hospitals, with FY2025 revenue of CAD 2.6 million (~29% YoY growth) and a customer footprint of 37 hospitals across Canada, the United Kingdom, and international pilot markets (Spain, Germany, Mexico). Distribution is primarily direct in Canada and through Mölnlycke Health Care in the United Kingdom, with HCA Healthcare acting as both a clinical-development partner for the US Phase 3 program and as a UK commercial channel. Beyond Steriwave, Ondine has four pipeline indications — chronic rhinosinusitis, burn and wound decolonization, endotracheal tube disinfection to prevent ventilator-associated pneumonia, and topical antiviral therapy for upper respiratory viruses — which extend the platform TAM but contribute no current revenue. The company has reported a CAD 29.5 million net loss in FY2025, driven principally by over CAD 21 million in LANTERN trial R&D spend.

Ondine Biomedical firmographics

Firmographics
Name
Ondine Biomedical
Legal name
Ondine Biomedical Inc.
Website
https://ondinebio.com
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Ondine Biomedical (LSE: OBI) is a Vancouver-based clinical-stage life sciences company that has commercialized Steriwave™, a CE-marked, FDA Fast Track-designated photodisinfection nasal decolonization therapy that reduces surgical site infections without contributing to antimicrobial resistance, sold to hospitals across Canada, the UK, and selected international markets.
Ownership category
akta.pro rank

Ondine Biomedical industry classification

Industry
Product category
Antimicrobial medical devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHANAD
Disinfection & Surface Decontamination (Wipes, Sprays, Fogging, UV Robots)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables

Keywords

  • Antimicrobial photodynamic therapy
  • Nasal decolonization therapy
  • Infection prevention devices
  • Non-antibiotic antimicrobial treatment
  • Surgical site infection prevention

Where Ondine Biomedical is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Ondine Biomedical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Steriwave Device and Consumables Sales: Sale of Steriwave photodisinfection system (capital equipment) and associated consumable components for nasal photodisinfection treatments. Revenue generated from hospital deployments and per-procedure consumables. FY2025 revenue was CAD 2.6 million with 29% year-over-year growth, driven by expanding hospital customer base.
  2. Product Pipeline Development: Development-stage products include chronic rhinosinusitis treatment, burn/wound decolonization, endotracheal tube disinfection for ventilator-associated pneumonia prevention, and topical antiviral therapy for upper respiratory tract including SARS-CoV-2. These pipeline products represent future revenue potential as they receive regulatory approvals.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Ondine Biomedical product offering

Product offering

Core offering

Ondine Biomedical develops and commercializes Steriwave, a light-activated antimicrobial photodisinfection medical device that performs rapid 5-minute nasal decolonization to eliminate pathogens (bacteria, viruses, fungi including MRSA, Staphylococcus aureus, Candida auris, and SARS-CoV-2) associated with healthcare-associated infections. The proprietary platform combines a photosensitizing solution with non-thermal laser light at specific wavelengths to generate singlet oxygen that destroys pathogens through oxidative burst without contributing to antimicrobial resistance. The product is sold as capital equipment together with per-procedure consumables to hospitals and healthcare systems for pre-surgical and ICU infection prevention.

Product overview

Ondine Biomedical Inc. is a Canadian life sciences company that has developed a patented photodisinfection platform technology for preventing and treating infections. The company's lead commercial product is Steriwave™, a rapid nasal decolonization therapy that eradicates pathogens in minutes using light-activated antimicrobial technology. The technology has been deployed in Canadian and UK hospitals, demonstrating up to 84% reduction in surgical site infections. The company also maintains a pipeline of products in development including treatments for chronic rhinosinusitis, burn and wound decolonization, endotracheal tube disinfection for ventilator-associated pneumonia prevention, and topical antiviral therapy for upper respiratory tract infections.

Differentiator

Problem solved

Functional benefit

Brands

  • Steriwave™: Rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics.

Products and services

  • Steriwave Nasal Photodisinfection System Steriwave is a light-activated antimicrobial medical device that performs rapid 5-minute nasal decolonization to eradicate a broad spectrum of pathogens (Staphylococcus aureus, MRSA, Candida auris, SARS-CoV-2 and other superbugs) in the nose. Designed for nurse-led in-clinic administration in hospitals, it eliminates pathogens associated with healthcare-associated infections without contributing to antimicrobial resistance. Real-world deployments at Vancouver General Hospital demonstrated up to 84% reduction in surgical site infections over the past decade.

Quantifiable outcome

  • Up to 84% reduction in surgical site infections at Vancouver General Hospital over past decade
  • +5 more outcomes

Companies that use Ondine Biomedical

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Ondine Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ondine Biomedical partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered minor and core.

  • LMU University Hospital MunichminorStrategic or Co-development Partner · 22 December 2025Research collaboration with Europe's highly ranked medical institution to pilot Steriwave in ENT patients, marking first German hospital pilot.
  • Royal Papworth Hospital NHS Foundation TrustminorStrategic or Co-development Partner · 2 October 2025Royal Papworth Hospital, one of the world's foremost cardiothoracic centres, launching pilot program with Steriwave for complex cardiac surgeries.
  • CAN Health NetworkminorStrategic or Co-development Partner · 12 May 2025Membership in CAN Health Network provides strategic support, insights and connections as Ondine works to scale its infection prevention technology across Canada.
  • Royal Columbian Hospital FoundationcoreStrategic or Co-development Partner · 19 March 2025Partnership for ICU pilot study (SMURF) evaluating nasal photodisinfection in critically ill patients. Study results accepted for publication in Journal of Critical Care, marking first-ever deployment of this therapy in ICU setting. Foundation provided research support and funding.
  • Leeds Teaching Hospitals NHS TrustcoreStrategic or Co-development Partner · 6 August 2024Dr. Paul Nix-led study at Leeds demonstrated 78.5% reduction in SSIs in complex brain surgery. Study results accepted for publication in Journal of Laryngology & Otology. Funded in part by Leeds Hospitals Charity.
  • HCA Healthcare UKcoreChannel Partner/ Reseller/ Distributor · 10 April 2024HCA Healthcare UK, one of the UK's leading private healthcare providers operating 30+ facilities, authorized Steriwave for use across its healthcare facilities. Professor Claire Hopkins at London Bridge Hospital demonstrated a 77% reduction in antibiotic use in endoscopic sinus surgery patients.
  • HCA HealthcarecoreStrategic or Co-development Partner · 27 January 2024HCA Healthcare is a key strategic partner conducting the pivotal Phase 3 LANTERN clinical trial across 14 US hospitals with over 5,200 patients. HCA invested US$4 million in Ondine and is partnered for FDA regulatory submission. HCA Healthcare is the largest healthcare system in the US with 184 hospitals and 2,000+ sites of care.
  • Mölnlycke Health CarecoreChannel Partner/ Reseller/ Distributor · 23 September 2023Mölnlycke Health Care serves as the UK distribution partner for Steriwave following partnership announced September 2023. Mölnlycke distributes the technology to NHS providers through NHS Supply Chain, enabling broad UK market access.
  • Mid Yorkshire Teaching NHS TrustcoreStrategic or Co-development Partner · 1 August 2023Partnership deploying Steriwave at two hospitals resulted in 71% reduction in post-surgical infections. Partnership won Excellence in Healthcare Partnership Award and shortlisted for HSJ Partnership Award. Technology now being evaluated across hospitals in England.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Ondine Biomedical competitors and assessment

Company assessment

Direct peers

  • PDI (Professional Disposables International): PDI's Prevantics and other nasal antiseptic products directly compete with Steriwave in the pre-surgical nasal decolonization category, targeting the same hospital infection-prevention buyers and similar clinical indications. Both compete for SSI reduction protocols in US hospitals.

Broad incumbents

  • Steris: Steris is a large, publicly-listed sterilization and infection-prevention company serving hospitals and life sciences with capital equipment, consumables, and services. It is an incumbent comparator for any hospital-grade antimicrobial/sterilization technology play, including Steriwave's infection-prevention value proposition.
  • 3M (Health Care): 3M's Health Care division sells skin and nasal antiseptics, surgical drapes, and infection-prevention products into the same hospital procurement channels as Steriwave. It is a broad incumbent competing for hospital infection-prevention budgets and SSI-reduction protocols.
  • Clorox Healthcare: Clorox Healthcare is a major incumbent in healthcare environmental disinfection (wipes, bleach cleaners, UV systems) sold into the same hospital infection-prevention channels as Steriwave. Comparable as a broad disinfectant incumbent competing for hospital HAI-reduction budgets.

Others

  • Mölnlycke Health Care: Mölnlycke is Ondine's UK distribution partner for Steriwave through NHS Supply Chain, and is itself a leading global wound care and infection-prevention company. Comparable as an infection-prevention participant serving hospitals, with direct overlap on the UK commercial channel.

Emerging players

  • Noxilizer: Noxilizer provides nitrogen dioxide-based no-touch sterilization for medical devices and pharmaceutical manufacturing. Comparable as an emerging non-traditional antimicrobial technology company targeting healthcare infection-prevention use cases adjacent to Steriwave.
  • Bioquell (Ecolab): Bioquell (now part of Ecolab) provides hydrogen peroxide vapor bio-decontamination systems for hospital rooms and life sciences facilities. Comparable as an emerging technology vendor in hospital infection prevention with overlap on HAI reduction value propositions.
  • DenMat: DenMat has historically offered Periowave and other light-activated antimicrobial products in dentistry, using a related photodisinfection approach. It is the closest direct comparable in photodynamic antimicrobial therapy, though operating in dental rather than hospital infection prevention.
  • Theralase Technologies: Theralase is a clinical-stage photodynamic therapy company developing light-activated therapeutics for cancer and infections. Comparable as a small-cap photodynamic therapy peer with similar scientific underpinnings to Ondine's photodisinfection platform.

Regional players

  • Xttrium Laboratories: Xttrium manufactures antiseptic and skin-prep products including chlorhexidine applicators used in US hospital decolonization protocols. Comparable as a US-focused antiseptic manufacturer competing with Steriwave for the pre-surgical nasal decolonization indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Ondine Biomedical social profiles

Digital presence

Ondine Biomedical compliance and trust

Trust signal

Compliance3 records

Ondine Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ondine Biomedical leadership team

Management profile

Number of profiles

Profiles13 records

Ondine Biomedical funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ondine Biomedical M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ondine Biomedical

What does Ondine Biomedical do?

Ondine Biomedical develops and commercializes Steriwave, a light-activated antimicrobial photodisinfection medical device that performs rapid 5-minute nasal decolonization to eliminate pathogens (bacteria, viruses, fungi including MRSA, Staphylococcus aureus, Candida auris, and SARS-CoV-2) associated with healthcare-associated infections. The proprietary platform combines a photosensitizing solution with non-thermal laser light at specific wavelengths to generate singlet oxygen that destroys pathogens through oxidative burst without contributing to antimicrobial resistance. The product is sold as capital equipment together with per-procedure consumables to hospitals and healthcare systems for pre-surgical and ICU infection prevention.

Is Ondine Biomedical a public or private company?

Ondine Biomedical is a public company. It is classified as public and is currently operating.

When was Ondine Biomedical founded?

Ondine Biomedical was founded in 1999. It employs 11 to 50 people.

Where is Ondine Biomedical based?

Ondine Biomedical is headquartered in Vancouver, Canada, in the North America region.

How does Ondine Biomedical make money?

Two revenue lines are on record. Steriwave Device and Consumables Sales are the primary driver. The others are product Pipeline Development.

Who are Ondine Biomedical's main competitors?

PDI (Professional Disposables International) is listed as a direct peer. Broad incumbents are Steris, 3M (Health Care) and Clorox Healthcare. Mölnlycke Health Care is listed as an others. Emerging players are Noxilizer, Bioquell (Ecolab), DenMat and Theralase Technologies. Xttrium Laboratories is listed as a regional player.

Does Ondine Biomedical have an API?

No public API is recorded for Ondine Biomedical.

What industry is Ondine Biomedical in?

Ondine Biomedical's product category is Antimicrobial medical devices. Its primary akta.pro industry code is HLAHANAD, Disinfection & Surface Decontamination (Wipes, Sprays, Fogging, UV Robots). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InvestegateOttawa Heart (UOHI) Study Results Published in JHIOndine Biomedical announced a peer-reviewed study in the Journal of Hospital Infection linking Steriwave nasal photodisinfection to a 52.8% relative reduction in conduit harvest site infections. The 32-month interrupted time series of 2,172 CABG procedures showed compliance rising from 35.4% to 93.3% and infections falling from 3.6% to 1.7%.TradingViewRCS - Ondine Biomedical - Ottawa Heart (UOHI) Study Results Published in JHIOndine Biomedical announced a peer-reviewed study in the Journal of Hospital Infection on Steriwave nasal photodisinfection for CABG patients. The 32-month interrupted time series of 2,172 procedures showed conduit harvest site infections fell from 3.6% to 1.7%, and compliance rose from 35.4% to 93.3%.InvestegateCardiac SSI Infection Tax at C$2,056 per SurgeryOndine Biomedical presented a health economic analysis at CCC 2026 estimating surgical site infections add C$2,056 per cardiac surgery, with a 10% capacity loss. The model uses a 6.7% baseline infection rate and C$30,689 incremental cost per infected patient.InvestegateTesting shows no MB-aPDT Resistance in VISA, MRSAOndine Biomedical reported that 20 sub-lethal exposure cycles of methylene blue photodisinfection did not select for resistance in multidrug-resistant S. aureus strains, including VISA, LRSA, and MRSA. The study also found no cross-resistance to 13 antibiotics, while a ciprofloxacin control developed resistance. The findings were presented at PDT 2026 in Nancy, France.YahooOndine Biomedical shares research that reinforces the potential of photodisinfectionOndine Biomedical reported that six Staphylococcus aureus strains, including MRSA, remained susceptible to its light-activated methylene blue treatment after 20 rounds of exposure, while ciprofloxacin-exposed bacteria developed resistance. The company plans to submit the full study to a peer-reviewed journal.Business & FinancialOndine Continues To Expand Hospital Adoption Of Steriwave Across The UK And Canada To Reduce Surgical Site InfectionsOndine Biomedical is expanding hospital adoption of Steriwave nasal decolonisation across the UK and Canada to reduce surgical site infections. The five-minute, nurse-administered treatment targets nasal pathogens, with trials showing reduced SSIs in orthopaedic and other procedures. The company cites real-world data, including a 78% reduction in SSIs for skull-base surgery at Leeds Teaching Hospitals.EIN PresswireOndine Continues to Expand Hospital Adoption of Steriwave Across the UK and Canada to Reduce Surgical Site InfectionsDartford and Gravesham NHS Trust adopted Ondine's Steriwave nasal photodisinfection to reduce surgical site infections in orthopaedic surgery. The five-minute, nurse-administered treatment targets nasal pathogens, offering a rapid, non-antibiotic alternative. The deployment follows a trial and reflects broader UK and Canadian hospital adoption.EIN PresswireOndine Continues to Expand Hospital Adoption of Steriwave Across the UK and Canada to Reduce Surgical Site InfectionsDartford and Gravesham NHS Trust adopted Ondine's Steriwave nasal photodisinfection to reduce surgical site infections in orthopaedic surgery. The five-minute, nurse-administered treatment targets nasal pathogens, offering a rapid, non-antibiotic alternative. The deployment follows a trial and reflects broader UK and Canadian adoption across multiple surgical settings.ProactiveinvestorsOndine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value - UPDATEOndine Biomedical reported a 51.5% reduction in surgical-site infections at Canada's largest cardiac centre after introducing Steriwave. Infections fell from 3.3% to 1.6% across 2,172 procedures, with patient compliance rising to 93.3%. The findings support broader adoption of point-of-care nasal photodisinfection in cardiac surgery.InvestegateCapital Access Window - Ondine Biomedical IncTrading in Ondine Biomedical's common shares on AIM was restored on October 20, 2026, after a Capital Access Window closed. The temporary suspension was lifted, and trading resumed from 7:30 am that day.